Abstract
Purpose: In defining the biological effects of the 10B(n, α)7Li neutron capture reaction, we have proposed a deterministic parsing model (ISHIYAMA-IMAHORI model) to determine the Compound Biological Effectiveness (CBE) factor in Borono-Phenyl-Alanine (BPA)-mediated Boron Neutron Capture Therapy (BNCT). In present paper, we demonstrate a specific method of how the application of the case of application to actual patient data, which is founded on this model for tissues and tumor. Method: To determine the CBE factor, we derived the following new calculation formula founded on the deterministic parsing model with three constants, CBE0, F, n and the eigen value Nth/Nmax. (1), where, Nth and Nmax are the threshold value of boron concentration of N and saturation boron density and CBE0, F and n are given as 0.5, 8 and 3, respectively. In order to determine Nth and Nmax in the formula, sigmoid logistic function was employed for 10B concentration data, Db(t) obtained by dynamic PET technique. (2), where, A, a and t0 are constants. Results and Conclusion: From the application of sigmoid function to dynamic PET data, it is concluded that the Nth and Nmax for tissue and tumor are identified with the parameter constants in the sigmoid function in Equation (2) as: (3). And the calculated CBE factor values obtained from Equation (1), with Nth/Nmax.
Highlights
Many types of pilot innovative accelerator-based neutron source for neutron capture therapy with lithium target were designed [1]-[3] and many inventions for the progressive power run-up were reported [4] [5]
In Japan, implemented deployment of accelerator-driven neutron source for Boron Neutron Capture Therapy (BNCT) was accomplished in 2014 in National Cancer Center, of which system was designed with the production of neutrons via threshold 7Li (p, n) 7Be reaction at 25 kW proton beam with energy of 2.5 MeV, which was designed to dovetail the narrow peak band resonance of lithium target and started its installation at middle of 2013
This BNCT device is expected to offer the potential for achieving the objects of which any treatment capable of sterilizing the primary tumor locally will result in a high probability of cure
Summary
Many types of pilot innovative accelerator-based neutron source for neutron capture therapy with lithium target were designed [1]-[3] and many inventions for the progressive power run-up were reported [4] [5]. In Japan, implemented deployment of accelerator-driven neutron source for Boron Neutron Capture Therapy (BNCT) was accomplished in 2014 in National Cancer Center, of which system was designed with the production of neutrons via threshold 7Li (p, n) 7Be reaction at 25 kW proton beam with energy of 2.5 MeV, which was designed to dovetail the narrow peak band resonance of lithium target and started its installation at middle of 2013 This BNCT device is expected to offer the potential for achieving the objects of which any treatment capable of sterilizing the primary tumor locally will result in a high probability of cure.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
